2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3364-3370

  Simons, Andrean L ^a   Ahmad, Iman M ^b   Mattson, David M ^a   Dornfeld, Kenneth J ^a   Spitz, Douglas R ^a  

^a UNIVERSITY OF IOWA   (United States)

^b HASHEMITE UNIVERSITY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; CATALASE; CISPLATIN; DEOXYGLUCOSE; GLUTATHIONE; GLUTATHIONE DISULFIDE; MACROGOL; SUPEROXIDE DISMUTASE; ANTINEOPLASTIC AGENT; CATALASE POLYETHYLENE GLYCOL; CATALASE-POLYETHYLENE GLYCOL; MACROGOL DERIVATIVE; POLYETHYLENE GLYCOL SUPEROXIDE DISMUTASE; POLYETHYLENE GLYCOL-SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG SENSITIVITY; GLUTATHIONE METABOLISM; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; DRUG EFFECT; DRUG POTENTIATION; HEAD AND NECK TUMOR; METABOLISM; SQUAMOUS CELL CARCINOMA;

ACETYLCYSTEINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTHIONINE SULFOXIMINE; CARCINOMA, SQUAMOUS CELL; CATALASE; CELL GROWTH PROCESSES; CISPLATIN; DEOXYGLUCOSE; DRUG SYNERGISM; GLUTATHIONE; HEAD AND NECK NEOPLASMS; HUMANS; OXIDATIVE STRESS; POLYETHYLENE GLYCOLS; SUPEROXIDE DISMUTASE;

EID: 34248142302     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3717     Document Type: Article

References (47)

1. Warburg O. On the origin of cancer cells. Science 1956; 132:309-14.
2. Weber G. Enzymology of cancer cells (first of two parts). New Eng J Med 1977;296:486-92.
3. Weber G. Enzymology of cancer cells (second of two parts). N Engl J Med 1977;296:541-51.
4. Lehninger AL. Biochemistry. New York: Worth Publishers, Inc.; 1976. p. 245-441, 467-71, 849-50.
5. Lee YJ, Galoforo SS, Berns CM, et al. Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. J Biol Chem 1998;273:5294-9.
6. Blackburn RV, Spitz DR, Liu X, et al. Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells. Free Radic Biol Med 1999;26:419-30.
7. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. Glucose deprivation-induced oxidative stress in human tumor cells: a fundamental defect in metabolism? Ann N Y Acad Sci 2000;899:349-62.
8. Andringa KK, Coleman MC, Aykin-Burns N, et al. Inhibition of glutamate cysteine ligase (GCL) activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose. Cancer Res 2006;66:1605-10.
9. 2 Mediate glucose deprivation-induced cytotoxicity and oxidative stress in human cancer cells. J Biol Chem 2005;280:4254-63.
10. Lin X, Zhang F, Bradbury CM, et al. 2-Deoxy-D-Glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 2003;63:3413-17.
11. Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 1994;21:20-7.
12. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
13. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 2005;39:696-703.
14. Arner ES, Nakamura H, Sasada T, Yodoi J, Holmgren A, Spyrou G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 2001;3:1170-8.
15. Biaglow JE, Miller RA. The thioredoxin reductase/ thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 2005;4:6-13.
16. Smart DK, Ortiz KL, Mattson D, et al. Thioredoxin reductase as potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 2004;64: 6716-24.
17. Kang H-J, Hong S-M, Kim B-C, Park E-H, Kisup A, Lim C-J. Effects of heterologous expression of thioredoxin reductase on the level of reactive oxygen species in COS-7 cells. Mol Cells 2006;22:113-8.
18. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4.
19. Townsend DM, Findlay VL, Tew KD. Gluthione transferases γ-glutamyl. Transpeptidases 2005;401: 287-307.
20. Spitz DR, Phillips JW, Adams DT, Sherman CM, Deen DF, Li GC. Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. J Cell Physiol 1993;156:72-9.
21. Laszlo J, Humphreys SR, Goldin A. Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. J Natl Cancer Inst 1960;24:267-80.
22. Shenoy MA, Singh BB. Non-nitro radiation sensitizers. Int J Radiat Biol 1985;48:315-26.
23. Anderson ME. Handbook of methods for oxygen radical research. Florida: CRC Press Inc; 1985. p. 317-23.
24. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980;106:207-12.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
26. 2-resistant cell lines. Do aldehydic by-products of lipid peroxidation contribute to oxidative stress? Biochem J 1990;267:453-9.
27. Mohanti BK, Rath GK, Anantha N, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996;35:103-11.
28. Sunderman FW, Jr., Sporn J, Hopfer SM, Sweeney KR, Chakraborty NG, Greenberg B. Platinum in blood mononuclear cells from patients after cisplatin therapy. Ann Clin Lab Sci 1990;20:379-84.
29. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001; 30:1191-212.
30. Turtle SW, Varnes ME, Mitchell JB, Biaglow JE. Sensitivity to chemical oxidants and radiation in CHO cell lines deficient in oxidative pentose cycle activity. Int J Radiat Oncol Biol Phys 1992;22:671-5.
31. Averill-Bates DA, Przybytkowski E. The role of glucose in cellular defences against cytotoxicity of hydrogen peroxide in Chinese hamster ovary cells. Arch Biochem Biophys 1994;312:52-8.
32. Landau BR, Lubs HA. Animal responses to 2-deoxyglucose administration. Proc Soc Exp Biol Med 1958;99:124-7.
33. Laszlo J, Humphreys SR, Goldin A. Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. J Natl Cancer Inst 1960;24:267-81.
34. Dwarkanath BS, Zolzer F, Chandana S, et al. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 2001;50: 1051-61.
35. Suzuki M, O'Dea JD, Suzuki T, Agar NS. 2-Deoxy-glucose as a substrate for glutathione regeneration in human and ruminant red blood cells. Comp Biochem Physiol B 1993;75:195-97.
36. Maschek G, Savaraj N, Priebe W, et al. 2-deoxy-D-glucose increases the efficacy of Adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004;64:31-4.
37. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003;4:889-901.
38. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Cisplatin resistance and oncogenes - a review. Anticancer Drugs 2000;11:225-36.
39. Veronese FM, Caliceti P, Schiavon O, Sergi, M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 2002;54: 587-606.
40. Spitz DR, Kinter MT, Roberts RJ. The contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts. J Cell Physiol 1995;165:600-9.
41. Arrick BA, Griffith OW, Cerami A. Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis. J Exp Med 1981;153:720-25.
42. Bailey HH. L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 1998;111:239-54.
43. Hamilton TC, Winker MA, Louie KG, et al. Augmentation of Adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985;34: 2583-86.
44. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54:4313-20.
45. Ikeda K, Miura K, Seiichiro H, Nobumasa I, and Naganuma A. Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum. Mol Cell Biochem 2001;219:51-6.
46. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003;22:7369-75.
47. Townsend DM, Shen H, Staros AL, Gate L and Tew KD. Efficacy of a glutathione S-transferase π-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther 2002;1:1089-95.